Pediatrix Medical Group, Inc.
$30.22+$0.28 (+0.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.8B
- P/E
- 11.1x
- EV / EBITDA
- 7.6x
- Revenue
- $1.9B
- Net margin
- 8.6%
- ROCE
- 12.9%
Price chart
Technical chartScreen technicals →+32.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +7.6%
- 3M
- +15.3%
- 6M
- +34.5%
- 1Y
- +32.9%
- 5Y
- +17.0%
52-week range
Day change +$0.28 (+0.9%) from $30 to $30 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MD, bought on each weekday since 2021.
News & filings
What Pediatrix Medical Group filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity rose from -13.0% to 19.1% between fiscal 2024 and fiscal 2025.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States.
Read moreShow less
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
- Sector
- Healthcare
- Shares outstanding
- 84.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.8B
- P/E
- 11.1x
- P/B
- 2.1x
- EV / EBITDA
- 7.6x
- EV / Sales
- 1.1x
- P/S
- 1.0x
- 52-week high
- $32.80
- 52-week low
- $18.82
Profitability
- Operating margin
- 12.1%
- Net margin
- 8.6%
- EBITDA margin
- 14.3%
- ROE
- 19.1%
- ROCE
- 12.9%
- ROA
- 7.4%
- Asset turnover
- 0.85
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.9B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -4.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -1.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -266.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $252.6M
Solvency
- Current ratio
- 1.66
- Debt / Equity
- 0.73
- Debt / Assets
- 0.28
- CFO / Net profit
- 1.64
- Cash / Market cap
- 20.4%
Where the revenue went
Of every $100 of FY2025 revenue, $9 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $1.4B |
| Revenue | Gross profit | $493.7M |
| Gross profit | Selling, general and administrative | $240.8M |
| Gross profit | Other operating expenses | $21.8M |
| Gross profit | Operating income | $231.1M |
| Operating income | Pretax income | $216.4M |
| Operating income | Interest and other expense | $14.7M |
| Pretax income | Tax and other | $51.0M |
| Pretax income | Net income | $165.4M |
Revenue and net profit
Revenue fell 4.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $2.0B | $66.3M |
| FY2023 | $2.0B | -$60.4M |
| FY2024 | $2.0B | -$99.1M |
| FY2025 | $1.9B | $165.4M |
Cash flows
FY2025: $271.1M from operations, $252.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $166.9M | $137.2M |
| FY2023 | $137.3M | $104.0M |
| FY2024 | $206.6M | $184.6M |
| FY2025 | $271.1M | $252.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.9B-4.9%1Y
- EBITDA
- $274.2M
- Net profit
- $165.4M
- Cash from operations
- $271.1M+31.2%1Y
- Free cash flow
- $252.6M+36.9%1Y
- Revenue CAGR, 3Y
- -1.0%
- Net profit CAGR, 3Y
- 35.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.9B | $274.2M | $165.4M | $252.6M | 19.1% | -4.9% | -266.9% |
Monthly returns
Month-by-month returns of MD across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.2B |
| Current assets | $763.5M |
| Non-current assets | $1.5B |
| Liabilities | $1.4B |
| Current liabilities | $458.9M |
| Non-current liabilities | $921.9M |
| Equity | $865.9M |
| Paid-in capital | $947.6M |
| Retained earnings | -$83.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; MD highlighted.
P/E against peers
MD trades at 11.1x earnings against a peer median of -11.4x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Pediatrix Medical Group, Inc.MDthis company | $1.8B | 11.1x | 2.1x | 19.1% | 7.6x |
| Stoke Therapeutics, Inc.STOK | $1.9B | -272.5x | 5.3x | -2.0% | -95.4x |
| Pulse Biosciences, Inc.PLSE | $1.9B | -25.6x | 23.1x | -90.2% | -23.6x |
| Zymeworks Inc.ZYME | $1.8B | -22.8x | 6.9x | -30.2% | -22.4x |
| Maravai LifeSciences Holdings, Inc.MRVI | $1.8B | -14.1x | 8.7x | -61.6% | -13.5x |
| Viridian Therapeutics, Inc.VRDN | $1.8B | -5.3x | 3.1x | -58.1% | -4.9x |
| Vericel CorporationVCEL | $1.8B | 110.3x | 5.1x | 4.7% | 60.3x |
| ANI Pharmaceuticals, Inc.ANIP | $1.8B | 23.0x | 3.3x | 14.5% | 10.3x |
| Nuvation Bio Inc.NUVB | $1.8B | -8.8x | 5.9x | -66.9% | -9.0x |
| Peer median | — | -11.4x | 5.6x | -44.1% | -11.2x |
Year-to-date ROI
MD since 1 January, against earlier years.
Historical volatility
MD's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 10.1% |
| FY2023 | 7.9% |
| FY2024 | 9.1% |
| FY2025 | 12.1% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.9B |
| Cost of revenueCost Of Revenue | $1.4B |
| Gross profitGross Profit | $493.7M |
| Operating expensesOperating Expense | $262.6M |
| Selling, general and administrativeSelling General And Administration | $240.8M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $21.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $21.8M |
| Total expensesTotal Expenses | $1.7B |
| Operating incomeOperating Income | $231.1M |
| Interest and other | |
| Pretax incomePretax Income | $216.4M |
| TaxTax Provision | $51.0M |
| Net incomeNet Income | $165.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.2B |
| Current assetsCurrent Assets | $763.5M |
| Non-current assetsTotal Non Current Assets | $1.5B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.4B |
| Current liabilitiesCurrent Liabilities | $458.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $921.9M |
| EquityTotal Equity Gross Minority Interest | $865.9M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $271.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $274.7M |
| Net income, continuing operationsNet Income From Continuing Operations | $165.4M |
| Depreciation and amortisationDepreciation And Amortization | $21.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $21.8M |
| Stock-based compensationStock Based Compensation | $18.1M |
| Deferred taxDeferred Tax | $52.2M |
| Deferred income taxDeferred Income Tax | $52.2M |
| Operating gains and lossesOperating Gains Losses | -$20.9M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$20.9M |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Change in working capitalChange In Working Capital | $41.8M |
| Other non-cash itemsOther Non Cash Items | -$3.6M |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | -$3.6M |
| Investing cash flowInvesting Cash Flow | -$18.3M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$18.3M |
| Capital expenditureCapital Expenditure | -$18.5M |
| Purchase of PP&EPurchase Of PPE | -$18.5M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$18.5M |
| AcquisitionsPurchase Of Business | -$23.2M |
| DisposalsSale Of Business | $30.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $6.8M |
| Purchase of investmentsPurchase Of Investment | -$29.9M |
| Sale of investmentsSale Of Investment | $26.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$3.2M |
| Other investing changesNet Other Investing Changes | -$3.5M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | — |
| Financing cash flowFinancing Cash Flow | -$107.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$107.5M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$20.8M |
| Net debt issuedNet Issuance Payments Of Debt | -$20.8M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$20.8M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$20.8M |
| Shares issuedIssuance Of Capital Stock | $3.2M |
| Common stock issuedCommon Stock Issuance | $3.2M |
| Net common stock issuedNet Common Stock Issuance | -$83.5M |
| Common stock repurchasedCommon Stock Payments | -$86.7M |
| Share buybacksRepurchase Of Capital Stock | -$86.7M |
| Other financing chargesNet Other Financing Charges | -$3.2M |
| Cash from discontinued financing activitiesCash From Discontinued Financing Activities | — |
| Change in cashChanges In Cash | $145.3M |
| Cash at the start of the yearBeginning Cash Position | $229.9M |
| Cash at the end of the yearEnd Cash Position | $375.2M |
| Free cash flowFree Cash Flow | $252.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Pediatrix Medical Group, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 11.1 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read